Follow-up of Children Exposed In Utero to 17 -Hydroxyprogesterone Caproate Compared With Placebo  

Oleh:

Northen, Allison T. ; Norman, Gwendolyn S. ; Anderson, Kristine ; Moseley, Lisa ; DiVito, Michelle ; and Others

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Obstetrics and Gynecology vol. 110 no. 04 (Oct. 2007), page 865.

Ketersediaan

Perpustakaan FK Nomor Panggil: O01.K.2007.04 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

OBJECTIVE: To assess whether there are evident adverse effects of 17 -hydroxyprogesterone caproate after in utero exposure. METHODS: This study evaluated surviving children of mothers who participated in a multicenter placebo-controlled trial of weekly intramuscular 17 -hydroxyprogesterone caproate, with a 2:1 allocation to 17 -hydroxyprogesterone caproate and placebo, respectively. The guardian was interviewed about the child’s general health. Children underwent a physical examination and developmental screen with the Ages and Stages Questionnaire. Gender-specific roles were assessed with the Preschool Activities Inventory. RESULTS: Of 348 eligible surviving children, 278 (80%) were available for evaluation (194 in the 17 -hydroxyprogesterone caproate group and 84 in the placebo group). The mean age at follow-up was 48 months. No significant differences were seen in health status or physical examination, including genital anomalies, between 17 -hydroxyprogesterone caproate and placebo children. Scores for gender-specific roles (Preschool Activities Inventory) were within the normal range and similar between 17 -hydroxyprogesterone caproate and placebo groups. CONCLUSION: 17 -hydroxyprogesterone caproate seems to be safe for the fetus when administered in the second and third trimesters.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali